Clinical trials: ASCVD
ASCVD
ACHIEVE Pilot Statins for Vascular Protection
ACHIEVE aims to increase statin usage among patients with ASCVD by having a pharmacist talk to patients and providers.
- Trial name
- ACHIEVE (NCT06551701)
- Testing
- Pharmacist call
- Where
- 2 sites in United States
- Volunteers
- 225 people
- Sponsor
- Duke University
ASCVD
Prospective Cohort Study of Panvascular Disease
To construct a comprehensive big data platform for Chinese people with panvascular disease, and establish a Chinese panvascular disease oriented to guide treatment decisions Cohort and imaging, biological database; According to…
- Trial name
- NCT06295861
- Testing
- no different intervention between the two cohort.
- Where
- 2 sites in China
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Dyslipidemias, High Cholesterol
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of…
- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia
- Trial name
- BROADWAY (NCT05142722)
- Testing
- Obicetrapib
- Where
- 181 sites in United States, China and 6 more
- Volunteers
- 2,530 people
- Sponsor
- NewAmsterdam Pharma
Primary Hypercholesterolemia, Mixed Dyslipidemia
A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
This study is to generate post-marketing safety and effectiveness data of inclisiran sodium in Indian patients as per approved indication i.e., primary hypercholesterolemia (heterozygous familial and non-familial) or mixed…
- Trial name
- NCT06386419
- Testing
- inclisiran
- Where
- 9 sites in India
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
The Learning Registry
The Learning Registry is a retrospective, exempt study. Researchers form the Duke Clinical Research Institute (DCRI) will utilize de-identified data managed by Cerner for population health analytics as part of a ongoing registry…
- Trial name
- NCT03911284
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Duke University
Hyperlipidemia, Atherosclerotic Cardiovascular Disease (ASCVD)
PCSK9 Inhibitors in Hyperlipidemia and Atherosclerosis
PCSK9 inhibitors, including evolocumab and alirocumab, are lipid-lowering therapies used in patients with hyperlipidemia and atherosclerotic cardiovascular disease.
- Trial name
- NCT07856264
- Volunteers
- 100 people
- Sponsor
- Fundación Santa Fe de Bogota
Atherosclerotic Cardiovascular Disease (ASCVD), Hypertension
Evaluation of an Integrated, Digital, Nurse-led, Remote Monitoring Care Pathway for Cardiovascular Risk Management
The goal of this observational study is to evaluate the implementation of a structured, digital, nurse-led, remote monitoring care pathway for cardiovascular risk management (CVRM).
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Hypertension, Dyslipidemia
- Trial name
- TELE-CVRM (NCT07208331)
- Where
- Netherlands
- Volunteers
- 750 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ASCVD, Impaired Fasting Glucose
High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and Hypertension
This study will evaluate the effect of high-dose rosuvastatin combined with telmisartan or amlodipine on glucose metabolism in ASCVD patients with impaired fasting glucose and hypertension.
- Conditions
- ASCVD, Impaired Fasting Glucose, Hypertension
- Trial name
- NCT03474562
- Testing
- Duowell®, Monorova® + Amlopin®
- Where
- 4 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Yuhan Corporation
Wearable Device, Cardiovascular Disease
HEARTS in Sync + CardioWatch 287-2
The goal of this interventional study is to evaluate the implementation, usability, and clinical outcomes of a wearable medical-grade device in a virtual Cardiac Rehabilitation (CR) program, titled HEARTS in Sync.
- Conditions
- Wearable Device, Cardiovascular Disease, ASCVD Management, CHF - Congestive Heart Failure
- Trial name
- NCT07322510
- Testing
- Remote Patient Monitoring with Corsano CardioWatch 287-2
- Where
- Canada
- Volunteers
- 216 people
- Sponsor
- Nova Scotia Health Authority
Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
This fictional study is an example of a ClinicalTrials.gov-style record. It describes a Phase 1/2 trial evaluating the safety and tolerability of TB-500 (a 17-23 fragment of thymosin beta 4) versus placebo in adults with stable…
- Trial name
- TBRIDGE-CV (NCT07487363)
- Testing
- TB-500
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Hudson Biotech
Atherosclerotic Cardiovascular Disease
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this…
- Trial name
- STaRT (NCT06858332)
- Testing
- Atorvastatin, Simvastatin, Rozuvastatin
- Where
- 20 sites in Russia
- Volunteers
- 2,382 people
- Sponsor
- Novartis Pharmaceuticals
Gene Polymorphism, ASCVD
NPC1L1 Gene Polymorphism and the Efficacy and Safety of Hybutimibe
Significant individual differences may lead to differences in patients' responses to drug therapy and lead to an increased incidence of adverse reactions.
- Trial name
- NCT06641661
- Testing
- Hybutimibe 10mg QD
- Volunteers
- 1,000 people
- Sponsor
- Qianfoshan Hospital
Inflammatory Bowel Diseases
Predictors of Subclinical Atherosclerotic Cardiovascular Diseases (ASCVD) in Patients With Inflammatory Bowel Disease
Heart disease and failure are the major causes of mortality and morbidity worldwide, despite significant advances in medical technologies in the diagnosis and treatment of the disease.
- Trial name
- NCT03868332
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assiut University
Hyperlipidemia, Hypercholesterolemia
Patient and Provider Assessment of Lipid Management Registry
The purpose of the Patient and Provider Assessment of Lipid Management Registry (PALM) is to gain a better understanding of physicians' cholesterol medication prescribing practices, patient and physician attitudes and beliefs…
- Conditions
- Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, Diabetes
- Trial name
- PALM (NCT02341664)
- Where
- 14 sites in United States
- Volunteers
- 7,658 people
- Sponsor
- Duke University
Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)
The purpose of this study is to see if ETC-1002 (bempedoic acid) is safe and well-tolerated versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current…
- Trial name
- NCT02666664
- Testing
- ETC-1002
- Where
- 104 sites in United States, Canada and 4 more
- Volunteers
- 2,230 people
- Sponsor
- Esperion Therapeutics, Inc.
Elevated Lipoprotein(a)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events
This is a randomized, double-blind, placebo-controlled Phase II trial evaluating the efficacy and safety of oral SAL0137 in adults with elevated Lp(a) and high cardiovascular risk.
- Trial name
- NCT07729475
- Testing
- SAL0137 Dose 1, SAL0137 Dose 2, SAL0137 Dose 3
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Atherothrombotic Diseases, Atherosclerotic Cardiovascular Disease (ASCVD)
Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease
The EPOCA study (Evaluation of a POlypill and Colchicine for risk reduction in patients with established Atherosclerotic cardiovascular disease) will be a randomized, superiority, parallel, 2x2 factorial, multicenter clinical…
- Trial name
- EPOCA (NCT06930885)
- Testing
- Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin), Colchicine 0.5 mg, Usual Care Group
- Where
- 13 sites in Brazil
- Volunteers
- 7,713 people
- Sponsor
- Hospital do Coracao
Cardiovascular Diseases
ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography
The primary objective of the ASA-3C trial is to evaluate the role of aspirin and high-intensity statin therapy, respectively, in individuals with severe coronary calcification (coronary calcium score ≥300) to prevent…
- Trial name
- ASA-3C (NCT06676280)
- Testing
- Aspirin, High-intensity statin, Guideline-directed statin therapy
- Where
- 32 sites in South Korea
- Volunteers
- 5,000 people
- Sponsor
- Jung-min Ahn
Dyslipidemia, Angina (Stable)
Validation of Remote Photoplethysmography (rPPG)-Derived Cardiovascular Parameters Against Standard Clinical Measurements and Risk Scores in a Community
The goal of this observational study is to evaluate whether a contactless camera-based technology, called remote photoplethysmography (rPPG), can accurately measure cardiovascular parameters and estimate cardiovascular risk in…
- Conditions
- Dyslipidemia, Angina (Stable), Coronary Artery Disease (CAD), Heart Disease
- Trial name
- NCT07502703
- Where
- Indonesia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Tarumanagara University
Hypercholesterolemia
A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting
This was a multicenter, non-randomized, non-interventional three-cohort study with prospective collection of primary data of treatment with newly initiated oral lipid lowering treatment on top of a statin (Oral LLT cohort), newly…
- Trial name
- NCT05362903
- Testing
- Inclisiran
- Where
- 121 sites in Germany
- Volunteers
- 1,868 people
- Sponsor
- Novartis Pharmaceuticals